BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

06/02/2026

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program, comments on the encouraging clinical findings from BriaCell's ongoing pivotal Phase 3 study which showed clinically meaningful benefit in heavily pre-treated metastatic breast cancer patients. Learn more: https://bit.ly/4ejBfu3

06/02/2026

Final Phase 2 data from BriaCell's Bria-IMT study, presented at , show 55% >1-year and 27% >2-year survival in heavily pre-treated metastatic breast cancer patients treated with the same Bria-IMT formulation as the Phase 3 study. There were no treatment-related discontinuations and no unexpected safety signals. Learn more: https://bit.ly/4ejBfu3

06/01/2026

Saranya Chumsri, MD, principal investigator in the Phase 3 study of Bria-IMT+CPI and Professor of Oncology at Mayo Clinic Florida, comments on positive Phase 2 clinical data presented at , including median overall survival rates as high as 16.6 months and a high rate of long-term survival in heavily pre-treated metastatic breast cancer patients. Learn more: https://bit.ly/4ejBfu3

06/01/2026

"We are increasingly optimistic with the early quality of life and biomarker data from our ongoing pivotal Phase 3 Bria-ABC trial demonstrating sustained clinical activity in patients with advanced MBC who did not respond to multiple prior treatments,"" noted William V. Williams, MD, BriaCell's President & CEO. Learn more: https://bit.ly/4ejBfu3

06/01/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced positive clinical data from three poster presentations at the 2026 ASCO Annual Meeting, taking place May 29–June 2, 2026 at McCormick Place, Chicago, Illinois. The presentations include two posters featuring data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, and one poster highlighting further analyses of Phase 2 data. Find details: https://bit.ly/4ejBfu3

05/28/2026

“Our positive clinical data across six presentations or abstracts at the ASCO 2026 Annual Meeting highlight the progress we are making in our clinical programs,” stated William V. Williams, MD, BriaCell’s President & CEO. To learn more about BriaCell's upcoming participation at , visit: https://bit.ly/4vogxA7

05/27/2026

Saranya Chumsri, M.D., Professor of Oncology at Mayo Clinic Florida and principal investigator in the Phase 3 study of Bria-IMT+CPI, comments on the encouraging clinical findings from the Phase 2 study evaluating a whole-cell vaccine in combination with anti-PD-1 therapy for patients. https://bit.ly/4vogxA7

05/26/2026

“We are highly encouraged by the sixth consecutive positive recommendation of the DSMB for continuation of BriaCell’s pivotal Phase 3 Bria-ABC study,” stated Dr. William V. Williams, President and Chief Executive Officer of BriaCell. For more information, visit: https://bit.ly/4dycs6h

05/26/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612). Find details: https://bit.ly/4dycs6h

05/22/2026

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women’s Cancer Program, comments on new data from the ongoing pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in patients to be presented at . Learn more: https://bit.ly/4vogxA7

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Category